2017
DOI: 10.1177/1179255817690768
|View full text |Cite
|
Sign up to set email alerts
|

Alirocumab in the Treatment of Hypercholesterolemia

Abstract: ABSTRACT:The role of low-density lipoprotein cholesterol (LDL-C) in the pathophysiology of atherosclerosis is well recognized, and statin therapy represents the standard of care for LDL-C lowering and reduction of cardiovascular risk. However, many patients fail to achieve LDL-C goals, whereas others are intolerant to statins due to side effects. Unfortunately, until recently, the efficacy of other nonstatin LDL-C-lowering agents was limited, achieving an LDL-C reduction of no more than 20%. Proprotein convert… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

0
8
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
4

Relationship

2
2

Authors

Journals

citations
Cited by 4 publications
(8 citation statements)
references
References 20 publications
0
8
0
Order By: Relevance
“…Moreover, as compared with placebo, alirocumab reduced levels of apolipoprotein B by 54%, reduced levels of total cholesterol by 37.5%, reduced levels of non-HDL-C by 52.3%, reduced levels of lipoprotein (a) by 25.6% and reduced levels of fasting triglycerides by 17.3%. On the other hand, as compared with placebo, alirocumab, raised levels of HDL-C by 4.6% and raised levels of apolipoprotein A1 by 2.9% [ 24 , 25 ].…”
Section: Alirocumabmentioning
confidence: 99%
See 3 more Smart Citations
“…Moreover, as compared with placebo, alirocumab reduced levels of apolipoprotein B by 54%, reduced levels of total cholesterol by 37.5%, reduced levels of non-HDL-C by 52.3%, reduced levels of lipoprotein (a) by 25.6% and reduced levels of fasting triglycerides by 17.3%. On the other hand, as compared with placebo, alirocumab, raised levels of HDL-C by 4.6% and raised levels of apolipoprotein A1 by 2.9% [ 24 , 25 ].…”
Section: Alirocumabmentioning
confidence: 99%
“…In a post hoc analysis, alirocumab, as compared with placebo, reduced the rate of major adverse cardiovascular events (death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization) by 48% (1.7 vs 3.3%; 95% CI: 0.31–0.90; nominal p =0.02) [ 24 , 25 ].…”
Section: Alirocumabmentioning
confidence: 99%
See 2 more Smart Citations
“…The human PCSK9 gene is located in the human chromosome 1p32.3 and encodes a 692-amino acid inactive glycoprotein, which undergoes an intramolecular self-catalytic cleavage in the endoplasmic reticulum [3]. trial, alirocumab, administered on top of maximally tolerated dose of statin, alone or in combination with other lipid-lowering agents, caused an additional 61.9% reduction in LDL-C levels, as compared with placebo [18,19]. …”
mentioning
confidence: 99%